Paper - WANFANG MED ONLINE

You Position: Home > Paper

新型磁对比剂钆贝葡胺在肝脏病变诊断中的临床应用

( views:212, downloads:114 )

Author:: No author available

Journal Title:: CHINESE JOURNAL OF RADIOLOGY

Issue:: 1

DOI:: 10.3760/j.issn:1005-1201.2004.01.020

Key Word:: No keyword available

Abstract： @@ 钆贝葡胺(Gd-BOPTA,商品名莫迪司,)由意大利Bracco公司首先推出,自1992年投入临床试验以来[1],至今已经历了临床Ⅰ、Ⅱ、Ⅲ期试验,并进入临床应用阶段[2].特殊的分子结构决定了它在肝脏疾病诊断中的优势.

Reference

[1]吴元魁,许乙凯,黄其鎏.超顺磁氧化铁粒子增强MRI区分肿瘤转移性与良性淋巴结的实验研究[J].2002,(6).
[2]汪登斌,陈克敏,周康荣.MnDPDP的基础研究[J].2001,(4).
[3]Riccardo Manfredi,Giulia Maresca,Richard L. Baron,etc.Gadobenate dimeglumine (BOPTA) enhanced MR imaging: Patterns of enhancement in normal liver and cirrhosis[J].1998,8(4).
[4]K O, Lim,D D, Stark,P T, Leese,etc.Hepatobiliary MR imaging: first human experience with MnDPDP.[J].1991,178.
[5]Bensel K,Davies A,Parker JR,etc.Pharmacokinetics and safety of gadobenate dimeglumine (multihance) in subjects with impaired liver function.[J].2002,37(5).
[6]Chiesa A,Petre C,Grazioli L,etc.Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study.[J].2000,215(3).
[7]Vogl T J,Pegios W,McMahon C,etc.Gadobenate dimeglumine--a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers.[J].1992.
[8]Kirchin M,Pirovano G,Spinazzi A,etc.MultiHance in the dynamic phase of contrast enhancement: a pictorial assessment.[J].1999,23(Suppl.1).
[9]Kirchin MA racco.it,Spinazzi A,Venetianer C,etc.Safety assessment of gadobenate dimeglumine (MultiHance): extended clinical experience from phase I studies to post-marketing surveillance.[J].2001,14(3).
[10]T J, Vogl,A, Stupavsky,W, Pegios,etc.Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation.[J].1997,205.
[11]Pirovano GP,Kirchin MA,Spinazzi A.Gadobenate dimeglumine (Gd-BOPTA). An overview.[J].1998,33(11).
[12]Alberto Spinazzi,Vito Lorusso,Gianpaolo Pirovano,etc.Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: Results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers[J].1999,6(5).
[13]Swan SK,LaFrance ND,Lambrecht LJ,etc.Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment.[J].1999,34(7).
[14]主编周康荣,陈祖望.体部磁共振成像[M].2000.
[15]Pirovano GP,Pistolesi GF,Morana G,etc.Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)--preliminary results of phase II clinical application.[J].1996,199(2).
[16]Kuwatsuru R,Kadoya M,Ohtomo K,etc.Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors.[J].2001,36(11).
[17]Grazioli L,Morana G,Caudana R,etc.Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings.[J].2000,35(1).
[18]P, Pavone,G, Patrizio,C, Buoni,etc.Comparison of Gd-BOPTA with Gd-DTPA in MR imaging of rat liver.[J].1990,176.
[19]Katholi R,Parker J,Bensel K,etc.Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency.[J].2000,36(6).
[20]Christoph de Haën,Vito Lorusso,Piero Tirone.Hepatic transport of gadobenate dimeglumine in TR- rats[J].1996,3(1).
[21]Hamm B,Kirchin M,Pirovano G,etc.Clinical utility and safety of MultiHance in magnetic resonance imaging of liver cancer: results of multicenter studies in Europe and the USA.[J].1999,23(Suppl.1).
[22]Wolfgang Schima,Jan Petersein,Peter F. Hahn,etc.Contrast-enhanced MR imaging of the liver: Comparison between Gd-BOPTA and mangafodipir[J].1997,7(1).
[23]Federle MP,Procacci C,Menni K,etc.Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine.[J].2001,221(3).
[24]Wolfgang Schima,Sanjay Saini,Jan Petersein,etc.MR imaging of the liver with Gd-BOPTA: Quantitative analysis of T1-weighted images at two different doses[J].1999,10(1).